Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.

Journal of virology - 23 Nov 2021

Acharya Arpan, Pandey Kabita, Thurman Michellie, Klug Elizabeth, Trivedi Jay, Sharma Kalicharan, Lorson Christian L, Singh Kamal, Byrareddy Siddappa N

Abstract excerpt

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 19 (COVID-19) pandemic. Despite unprecedented research and developmental efforts, SARS-CoV-2-specific antivirals are still unavailable for the treatment of COVID-19. In most instances, SARS-CoV-2 infection initiates with the binding of Spike glycoprotein to the host cell ACE2 receptor. Utilizing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Monophosphate
Share to Angiotensin-Converting Enzyme 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemistry, Pharmaceutical

Share to COVID-19 Drug Treatment

Share to Drug Design

Share to Inhibitory Concentration 50

Share to Spike Glycoprotein, Coronavirus

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 34550770
DOI: 10.1128/JVI.01437-21
PMCID: PMC8610590

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.PMID 34550770Read ↗

Inhibitors of SARS-CoV‑2 Entry: Current and Future OpportunitiesSemantic proximity Read ↗

In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19Semantic proximity Read ↗

Inhibition of ACE2‐Spike Interaction by an ACE2 Binder Suppresses SARS‐CoV‐2 EntrySemantic proximity Read ↗

Identification of Potent Small Molecule Inhibitors of SARS-CoV-2 EntrySemantic proximity Read ↗

Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of SpikeSemantic proximity Read ↗

SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host CellsSemantic proximity Read ↗

Homology Modeling and Molecular Dynamics-Driven Search for Natural Inhibitors That Universally Target Receptor-Binding Domain of Spike Glycoprotein in SARS-CoV-2 Variants.Semantic proximity Read ↗

Broad-Spectrum Coronavirus Inhibitors Discovered by Modeling Viral Fusion DynamicsSemantic proximity Read ↗

The Pan-African Natural Products Library Compounds Oleanolic Acid, Poinsettifolin B, and Rhuschalcone III Disrupt SARS-CoV-2 Spike-Host ACE2 Interactions and SARS-CoV-2 ReplicationSemantic proximity Read ↗

Small-Molecule <i>In Vitro</i> Inhibitors of the Coronavirus Spike – ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2Semantic proximity Read ↗

Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptidesSemantic proximity Read ↗

SARS-CoV-2: Origin, Evolution, and Targeting InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.